ICU Medical, Inc. $ICUI Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB cut its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 11.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,758 shares of the medical instruments supplier’s stock after selling 4,380 shares during the quarter. Nordea Investment Management AB’s holdings in ICU Medical were worth $4,705,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ICUI. AQR Capital Management LLC raised its position in shares of ICU Medical by 2.5% in the first quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after buying an additional 229 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after acquiring an additional 560 shares during the last quarter. United Services Automobile Association acquired a new stake in ICU Medical during the first quarter worth approximately $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in ICU Medical by 32.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after acquiring an additional 16,680 shares during the period. Finally, Intech Investment Management LLC grew its stake in ICU Medical by 38.6% in the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after acquiring an additional 3,326 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

ICUI has been the topic of a number of recent analyst reports. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday, February 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Piper Sandler upped their target price on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research note on Friday, February 20th. Finally, KeyCorp increased their target price on ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $179.33.

ICU Medical Price Performance

ICU Medical stock opened at $127.65 on Friday. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $160.29. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.15 and a current ratio of 2.39. The firm has a 50 day moving average price of $143.98 and a 200 day moving average price of $138.07. The company has a market cap of $3.19 billion, a price-to-earnings ratio of 6,385.69, a PEG ratio of 1.90 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.23. The company had revenue of $535.94 million for the quarter, compared to the consensus estimate of $541.20 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical’s revenue was down 14.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.11 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts predict that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.